Brooklyn ImmunoTherapeutics Inc. (BTX): Price and Financial Metrics
BTX Price/Volume Stats
| Current price | $4.10 | 52-week high | $10.10 |
| Prev. close | $0.21 | 52-week low | $0.17 |
| Day low | $3.62 | Volume | 127,880 |
| Day high | $4.20 | Avg. volume | 515,543 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $1.28 | Market Cap | 241.30M |
BTX Stock Price Chart Interactive Chart >
Brooklyn ImmunoTherapeutics Inc. (BTX) Company Bio
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.
Latest BTX News From Around the Web
Below are the latest news stories about BROOKLYN IMMUNOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BTX as an investment opportunity.
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies CongressSAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston. Details of Presentation Title: Avoiding Vector Integration Using mRNA Vectorization of |
Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis BiotherapeuticsThe Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Exacis’ iNK and iT cells, made using non-viral, episome-free cell engineering technology, include advanced ‘stealthing’ edits, and can target virtually any cancer antigen SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop |
Brooklyn ImmunoTherapeutic changing name to Eterna Therapeutics on MondayMARKET PULSE Brooklyn ImmunoTherapeutics Inc. (BTX) said Tuesday it’ll change its stock trading ticker to ERNA on Monday, Oct. 17, as part of a name change to Eterna Therapeutics Inc. The San Diego-based clinical stage biopharmaceutical company said the new name reflects its focus on developing advanced therapies using its patented mRNA cell engineering technologies. |
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate UpdatesNew name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s shares to trade under new ticker symbol “ERNA” starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Na |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, investor! |
BTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -99.48% |
| 5-year | -96.99% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -6.92% |
| 2020 | 1.82% |
| 2019 | 12.82% |
Loading social stream, please wait...